Blog
RSS FeedPosted by Michael Wonder on 04 May 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping
3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...
Posted by Michael Wonder on 03 May 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...
Posted by Michael Wonder on 03 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...
Posted by Michael Wonder on 03 May 2023
Voclosporin with mycophenolate mofetil for treating lupus nephritis
3 May 2023 - NICE has issued evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in ...
Posted by Michael Wonder on 03 May 2023
Ripretinib for treating advanced gastro-intestinal stromal tumour after three or more treatments
3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 24 Apr 2023
NICE collaborates with international partner agencies to streamline the confidential marking process
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
Posted by Michael Wonder on 20 Apr 2023
Tezepelumab for the treatment of patients with severe asthma
20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years ...
Posted by Michael Wonder on 19 Apr 2023
Onasemnogene abeparvovec for the treatment of patients with presymptomatic spinal muscular atrophy
19 April 2023 - NICE has published Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for the treatment of babies aged 12 months ...
Posted by Michael Wonder on 19 Apr 2023
Eladocagene exuparvovec for the treatment of patients with aromatic L-amino acid decarboxylase deficiency
19 April 2023 - NICE has published evidence based recommendations on eladocagene exuparvovec (Upstaza) for the treatment of patients 18 ...
Posted by Michael Wonder on 17 Apr 2023
Daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma
17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...
Posted by Michael Wonder on 13 Apr 2023
‘A global outlier’: how drug firms are fighting back against UK tax increases
13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...
Posted by Michael Wonder on 13 Apr 2023
How ‘surrogate outcomes’ influence long-term health outcomes
13 April 2023 - NICE working with international organisations to develop guidance. ...
Posted by Michael Wonder on 12 Apr 2023
HTA barriers for conditional approval drugs
12 April 2023 - The objective of this study is to assess whether conditionally approved drugs face higher probabilities of HTA ...
Posted by Michael Wonder on 08 Apr 2023
NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals
6 April 2023 - Ground breaking commercial deals for the anti-cancer medicine olaparib have paved the way for hundreds to benefit ...